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ABSTRACT

Photodynamic Therapy Induces Oxidation in Breast and
Brain Cancer Cell Lines
by
Sarah Ann Ziegler
Dr. Stephen W. Carper, Examination Committee Chair
Professor o f Chemistry
University o f Nevada, Las Vegas
Photodynamic Therapy (PDT) is a cancer treatment modality that utilizes both a
photosensitizing drug and light irradiation. To better understand how PDT induces cell
death, four human breast cancer (DC4, DB46, MCF7 and MDA-MB-435) and two rat
glioma (BT 4 C and F98) cell lines were treated with 635 nm light from a diode laser
following incubation with either Photofrin® or aminoleuvilinic acid (ALA). Cellular
responses were evaluated by: clonogenic survival, cell cycle distribution, fluorescent
microscopy, protein oxidation and lipid oxidation assays. PDT was able to induce both
apoptosis and necrosis as well as protein and lipid oxidation. Even though breast cancer
cells were more sensitive to Photofrin® as compared to ALA-mediated PDT, there was
less oxidation in the Photofrin® treated cells. While it appears that Photofrin® and ALAmediated PDT caused cell death by two different mechanisms, bulk oxidation o f either
lipids or proteins was not correlative to cellular survival.
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CHAPTER 1

INTRODUCTION
Despite more anti-cancer treatment advances, cancer is the second leading cause o f
death in the United States. More than one million new cases o f cancer were diagnosed in
2005 alone (1). There are many treatment modalities currently available for cancer
including surgery, chemotherapy, radiation, hormonal treatments and immunotherapy.
These treatments have various side effects including pain, nausea, vomiting, hair loss,
skin tenderness and fatigue. Unfortunately, with so many treatment options available,
there is still the risk o f cancer recurrence. Recurrent cancer is more difficult to treat due
to gene mutations which cause resistance to anti-cancer therapies. Even though there are
many new treatment options available, scientists have not eliminated the high mortality
rate associated with cancer. Thus, it is o f the utmost importance to develop more
advanced and personalized treatment modalities.
Breast cancer was diagnosed in more than 200,000 women in the United States
annually (2 ); furthermore breast cancer was the second most deadly form o f cancer in
women, with more than 40,000 fatalities reported in 2005(1). In the treatment o f breast
cancer, combination therapies are commonly used. Most women who are diagnosed with
breast cancer will undergo a surgical resection to remove the tumor. In the majority o f
cases surgical resection is used in conjunction with focused radiation therapy to the tumor
bed. Women who have breast cancer and are estrogen receptor (ER) positive or
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progesterone receptor (PR) positive may also be given anti-hormone treatments to retard
the growth and spread o f the cancer (3). Chemotherapy can also be administered in the
form o f a drug cocktail including multiple anti-cancer agents; however even with this
complex treatment plan, breast cancer proves deadly for many women.
Unfortunately, many breast cancer patients develop recurrent tumors on the chest
wall after preliminary treatments. Up to 5% o f breast cancer patients will be affected by
chest wall recurrence (4). Treatment o f these recurrent sites include the same therapies
used at the initial tumor location. The second round o f treatment is sometimes
unsuccessful, leaving physicians with few options. If these lesions are left untreated they
can spread and ulcerate causing possible infection and bleeding (5). Many aggressive
treatment modalities for chest wall recurrence can be fatal due to their ability to
compromise the chest wall and the proximity o f the lungs to the tumors (6 ). Chest wall
recurrence is usually very painful and requires the patient to use analgesic pain
medications. Since current treatments for chest wall lesions usually result in a recurrence
of the tumors, a new treatment modality is needed. Photodynamic therapy has been
studied for use with these tumor sites with promising results (7).
Photodynamic therapy (PDT) is an underutilized treatment modality and needs to
be more aggressively studied in the U.S. The majority o f publications on PDT research
are o f European and Asian origin. PDT has advantages over other treatment modalities
in its ability to target specific tumor sites. PDT is administered in a two part treatment
that involves the delivery o f a photosensitizing drug followed by light irradiation. A
photosensitizer is a chemical that absorbs light and causes a chemical or physical change
in another molecule ( 8 ). By using both a photosensitizer and a laser light, the clinician is

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

able to specifically target tumor sites and induce cell death in a localized area (9). The
photo sensitizer uptake into the tumor cells happens preferentially to normal cells ( 1 0 ).
This preferential uptake enhances PDT’s ability to target and localize damage to tumor
cells. By combining a controlled light irradiation and preferential uptake o f the
photosensitizer into tumor cells, ubiquitous cell damage to normal cells can be
minimized.
PDT works by harnessing energy from light and using it to induce cytotoxicity in
tumor cells. The photosensitizing drug absorbs light energy within the cell and is
elevated to an excited singlet state (Fig. 1, page 13). Subsequently, the photosensitizer is
able to intersystem cross to an excited triplet state. Once in a triplet state, the
photosensitizer can undergo two types o f reactions to cause oxidative stress and/or
damage (11). The Type 1 reaction, through the transfer o f an electron or hydrogen,
causes the formation o f free radical species (Fig. 2, page 14). These free radicals can
lead to the formation o f superoxides. The Type 11 reaction is characterized by the
formation o f reactive oxygen species (ROS) through the excitation o f oxygen fi-om a
triplet ground state to an energized singlet state. The reactive oxygen species and
superoxides cause cell damage, leading to cell death.
Besides being able to absorb light and cause the formation o f reactive oxygen
species within the cell, many o f the photosensitizers have intrinsic fluorescent properties.
Fluorescence happens when the photosensitizer is able to absorb light energy and reach
an excited singlet state. If this energy is rapidly released, fluorescence occurs by the
emission o f a photon. The light emission o f the molecule is at a longer wavelength and a
lower energy level than the light used to initially excite the photosensitizer. This
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fluorescent property o f the photosensitizers has been utilized by physicians to help in the
diagnostic process o f cancer therapy. By giving a patient a systemic photosensitizer dose
and then exciting the photosensitizer with light, clinicians are able to visualize the whole
tumor region with the naked eye. The photosensitizers’ fluorescent properties also give
scientists an easy way to quantify the amount o f photosensitizer within the tumor cells.
But, like all treatments, there are possible side effects and problems with PDT
treatment. After giving the patient a photosensitizer, the patient’s whole body will
become sensitized to light. Depending on the photosensitizer used this time may range
from two days to a month or more, causing the patients to keep their skin covered at all
times and wear protective eye wear. There is also the possibility o f pain and burning near
the treatment site or adverse side effects to the photosensitizer drug, but these side effects
are rare.
One of the limitations o f PDT is the availability o f the light source to reach the
tumor area. In order for PDT to be effective, the laser light must be able to reach the
tumor location. Many researchers and physicians are exploring new ways to overcome
this obstacle, but PDT may not be a good treatment option for all types o f cancers.
Another limitation o f this treatment is the absorbance o f the photosensitizer into the
tumor cells. At the cellular level the photosensitizer must be intracellularly located to be
effective in inducing cytotoxicity. This potentially could be a problem in treatment o f
brain cancer if the drug is not able to cross the blood brain barrier. It also limits
researchers in the type o f photosensitizer that can be used in PDT as it must be able to
cross the plasma membrane.
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Photosensitizing drugs must possess certain qualities to be effective for their use
in PDT. Photosensitizing drugs can be taken up by the tumor cells inducing cytotoxic
damage following light exposure. The drugs, or their metabolites, must also be able to
absorb light in order to release energy to oxygen. It is also a good quality if the
photosensitizer will be preferentially absorbed in tumor cells over normal cells. Many
different photosensitizing drugs are being tested for their effectiveness in PDT.
The wavelength of light that is used in conjunction with PDT is also being
optimized. Blue light has a higher amount o f energy and therefore would be more
efficient in causing cytotoxic damage. Many o f the photosensitizers have absorbance
peaks in the blue region rather than at longer wavelengths. But the problem with utilizing
blue light is that it has a limited penetration depth through tissues. When treating tumor
sites it is important to be able to penetrate through the skin to reach the basal level o f the
tumor bed. By using a red light at a longer wavelength, physicians are able to get a much
deeper tissue penetration and are also able to treat tumors that are located under the skin
without surgically exposing them. Red laser light at 635 nm is preferentially utilized to
blue light in PDT in many settings because o f its ability to penetrate tissues.
One drug that is being used in conjunction with PDT is 5-aminoleuvilinic acid
(ALA). ALA is a pro-drug that increases the production o f the photosensitizer,
protoporpyhrin IX (PpIX) within cells. This pro-drug has been FDA approved for
treatment in cancer patients. ALA is a biosynthetic molecule that is one o f the precursors
in the heme pathway. ALA is a small molecule that is incorporated into the tumor cells.
Once it is in the cell it is used to synthesize PpIX. PpIX is the photosensitizer utilized in
ALA-mediated PDT. By extrinsically increasing the levels o f ALA, the pathway can be
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manipulated to produce a large concentration o f PpIX within the cell. This molecular
excess is preferentially found in tumor cells as compared to normal cells. By having an
increased concentration o f PpIX, the tumor cells become photosensitive and a target for
PDT.
ALA-mediated PDT uses the heme biosynthetic pathway (Fig. 3, page 15). The
metabolism o f heme is tightly regulated within all cells under physiological conditions.
ALA is synthesized in the mitochondria by the enzyme ALA synthase via a condensation
o f glycine and succinyl CoA. ALA synthase can be regulated by negative feed-back
inhibition, and is the committed step in the anabolism o f heme. ALA is transported out
o f the mitochondria to the cytosol where porphobilinogen, uroporphyrinogen III and
coproporphyrinogen III are synthesized as the next three steps in the heme pathway.
Coproporphyrinogen III is transported back into the mitochondria where through two
steps, PpIX is synthesized. The final step in the heme pathway is the incorporation o f
ferrous iron into PpIX by the enzyme ferrocheletase to create heme within the
mitochondria. Eight ALA molecules total are used in the formation o f each PpIX.
One of the advantages o f using ALA, is being a biosynthetic molecule, the body
already has a system to metabolize ALA and PpIX. This results in a lower time o f
photosensitivity after PDT has been administered. Other photosensitizers that are not
normally found within the body, have a much longer rate o f excretion from the body and
result in longer photosenitization after PDT treatment. ALA can also move across the
blood brain barrier and therefore can be utilized in the treatment o f gliomas.
Photofrin® is a FDA-approved commercially available proprietary photosenitizer
that is produced by Axcan Pharma Inc. Photofrin® is a mixture o f porphyrin ring systems
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that exist as monomers, dimmers and oligomers. Due to similar chemical architectures,
Photofrin® and PpIX both absorb light in the red region o f the spectra around 635nm.
Patients treated with Photofrin®-mediated PDT have a longer time frame o f
photo sensitization due to the longer time needed to catabolize and excrete Photofrin®.
This in vivo time frame can be as long as a month after PDT with Photofrin® (1 1).
There are many other photosensitizers that are being tested to be used with PDT.
Another commercially available photosensitizer is Foscan (m-tetrahydroxyphenylchlorin). Foscan is a porphyrin ring photosensitizer that localizes to the
endoplasmic reticulum and golgi within the cell (12). Another type o f photosensitizer
that is currently under investigation is a beta-carboline derivative that directs the
oxidative damage caused by PDT by intercalating into DNA (13). This mechanism
provides a direct approach to cause DNA damage and induce cell death. Additionally,
Acridine Orange is also a photosensitizer used in PDT, but is excited in the blue region
(14).
Production o f reactive oxygen species is one o f the outcomes o f PDT treatment.
Reactive oxygen species can cause cellular damage to many different molecules within
the cell including DNA, proteins and lipids. Oxidation o f molecules can render them
inactive. This can also be a localized event only occurring in one part o f the cell or a
total cell event. Oxidative stress can lead to cell death, if the damage is extensive and
beyond the repair capabilities o f the cell.
Proteins are targets for oxidative damage within the cell. Within proteins the side
chains o f the amino acids are sensitive to oxidative stress. Cysteine residues can be
oxidized to form disulfide bonds. Other side chains that can easily be oxidized are found
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on histidine, methionine, tryptophan and tyrosine. Tyrosine side chains can be oxidized
to form dimers between two oxidized tyrosine residues (15). This can greatly affect the
function o f enzymes that rely on tyrosine residues within their active site.
Lipids are also targets for oxidation within cells. W hen reactive oxygen species
react with arachidonic acid, prostaglandin endoperoxide is formed (16). Reduction o f the
prostaglandin endoperoxide, with the subsequent breakdown o f the product will produce
malondialdehyde (MDA). MDA is able to form adducts with DNA and is thought to be
mutagenic in cells (17). The measurement o f MDA as a way to quantitate the amount o f
oxidation within the cell is widely used (18).
Cells have intrinsic antioxidants to control the damage done by reactive oxygen
species. Reactive oxygen species are synthesized under normal physiological conditions
during electron transport chain reduction o f oxygen and the oxidation o f ATP. To control
the harmful effects that reactive oxygen species induce, the cell contains antioxidant
molecules. One o f these is a-tocopherol (vitamin E) which can be incorporated into the
lipid membranes. a-tocopheroTs mechanism o f action is through the scavenging o f free
radicals (Fig. 4, page 16). The benzene ring o f the a-tocopherol is able to accept an
electron to form a stable resonance structure. The levels o f vitamin E in the cell can be
manipulated by changing the concentration o f vitamin E within the cellular media.
Another antioxidant within the cell is glutathione (GSH). GSH is a tripeptide
molecule found in the cell consisting o f glutamate, cysteine and glycine residues. GSH
can reduce H 2 O 2 molecules with the help o f glutathione peroxidase, through the cysteine
residue’s loss o f a hydrogen atom (Fig. 5, page 17). When this occurs one molecule o f
H 2 O 2 can be broken down into two water molecules. Two GSH molecules will make a
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disulfide bond to form glutathione disulfide (GSSG). GSSG can then be recycled back to
GSH by the enzyme glutathione reductase. Glutathione reductase uses one molecule o f
NADPH to regenerate GSH.
The synthesis o f GSH is accomplished through two enzymes, y-glutamylcysteine
synthetase and glutathione synthetase (Fig. 6 , page 18). These two enzymes link the
glutamate residue and the cysteine residue through an isopeptide bond. The glycine
residue is added last through a peptide bond to complete the molecule. One way to
extrinsically regulate GSH within the cell, is by the application o f buthionine sulfoximine
(BSO). BSO is a y-glutamylcysteine synthetase inhibitor that can reduce GSH levels
within the cell by 75% (19).
There are two different cellular death pathways. Apoptosis is programmed cell
death and is a tightly regulated process. Apoptosis can be signaled either extrinsically
through a death receptor or intrinsically by cell stress. There are many different
pathways that can lead to apoptosis. One o f them is through the release o f cytochrome c
from the mitochondria. Cytochrome c release starts a cascade that signals for apoptosis,
but itself needs to be signaled to be released. Cytochrome c once released from the
mitochondria binds the Apaf-1 and leads to the cleavage o f procaspase-9 to caspase 9.
Caspase 9, Apaf-1 and cytochrome c bind together to form the apoptosome complex.
The apoptosome complex can then lead to the cleavage and activation o f caspase-3 which
cleaves ICAD releasing CAD which migrates into the nucleus and starts DNA
fragmentation. As apoptosis continues, proteins are cleaved by proteases and lose their
function. The cellular contents are packaged and enzymes are rendered inactive.
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Apoptosis is a slower more controlled type o f cell death that leads to less stress on
neighboring cells.
Necrosis is another type o f cellular death. Necrosis is a faster type o f cell death
that is not programmed or controlled. Necrosis is much harder to study and identify
because o f its chaotic nature. Necrosis can be characterized by the cell rupture or loss o f
an intact cellular membrane. Necrosis is not signaled by caspase activation or Bax
migration to the mitochondria as is apoptosis. Because necrosis is uncontrolled, it results
in the release o f the cellular contents into the cellular matrix. These contents contain
proteases and the lysomal contents and can cause damage to neighboring cells. When
necrosis happens in the body, an immune response can be triggered causing
inflammation. If necrosis occurs to a large amount o f cells, it can cause damage to
neighboring tissues that are otherwise healthy.
There are many hallmarks o f apoptosis that can be used to characterize this type
o f cell death as compared to necrosis. One o f these is that phosphytidyl serine, a cellular
membrane component, can be found on the outside o f the cellular membrane instead o f
only on the inner membrane side where it normally is found. Another hallmark of
apoptosis is the activation o f caspases. Caspases are unique to apoptosis. Some
important caspases in apoptosis include caspase 3,

8

and 9. There are many more signs

that can be used to determine what type o f cell death the cells are undergoing. This
includes DNA laddering which determines if DNA fragmentation has occurred. Also the
ability o f certain proteins to maintain their function can be tested including mitochondrial
enzymes. The ability o f the cell to preclude certain dyes, for example Hoechst, can
additionally greatly facilitate the identification o f the mode o f cell death.

10
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Heat shock proteins (hsps) are a family o f proteins that are transcribed within the
cell when the cell undergoes certain stresses (e.g., elevated temperature). Other stresses
to the cell have also been identified as inducing the production o f heat shock proteins,
including many different types o f cancer treatments (20, 21). Heat shock proteins are
usually classified as chaperone proteins and can have protective effects for cells
undergoing stress. This protection is an unwanted side effect to anti-cancer therapies and
can help a cancer cell to survive. Understanding the function o f hsps is important to
cancer researchers because of their abilities to protect cancer cells.
Hsp27 is a heat shock protein that is 27kD in size. Hsp27 is found elevated in
34% o f breast cancers (22). These 34% o f breast cancers that are elevated in levels o f
Hsp27 will have enhanced resistance to chemotherapy. The function o f Hsp27 is
regulated by up to three phosphorylation events, furthermore, Hsp27 has been found to
form dimers and oligomers within the cell. Hsp27 is also able to disrupt the apoptosis
signaling within the cell by binding to cytochrome c and inhibiting the apoptosis signal
(23,24). There are still other roles that hsp27 plays within the cell, but the exact purpose
has not been determined and is currently being studied in many laboratories.
To further study the role o f hsp27 in the protection against PDT two cell lines
were used in the studies reported here, that have been engineered to express different
levels o f hsp27. The DC4 and DB46 cells, from the parent cell line MDA-MB-231, have
both been transfected with plasmids to regulate the constitutive levels o f hsp27 (25). The
DB46 cells produce an elevated level o f hsp27, while the DC4 cells produce a normal
level o f hsp27 and are the control cell line for the DB46 cells. The DB46 cells produce a
level o f hsp27 that is equivalent to the DC4’s after a heat shock treatment (24).

11
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A rat glioma model o f brain cancer was also investigated to better understand the
global ramifications o f PDT. Malignant gliomas is difficult to treat in patients and the
prognosis o f patients diagnosed with a malignant glioma is poor. PDT has been shown to
be a treatment for brain cancer patients and has improved the survival o f these patients
(26). Comparing a glioma model to that o f a breast cancer model allows for the ability
to compare two very different cellular types. Glial cells are highly specialized within the
body. One thing that makes them unique is their lipid content. Glial cells contain lipids
that are not found in other parts o f the body. These include a class o f lipids called
sphingolipids. Sphingolipids play an important part in the formation o f myelin sheaths.

Hypothesis - Both ALA and Photoffin®-mediated PDT will be effective in killing breast
cancer cells in a dose dependent manner. This cytotoxicity will be induced through the
formation o f oxidized proteins and lipids. Both necrosis and apoptosis will be induced by
both photosensitizers in a dose dependent manner. The switch between apoptosis and
necrosis is dependent on the amount o f lipid or protein oxidation. This model o f either
protein or lipid oxidation causing necrosis or apoptosis, will be universal, operating in a
rat glioma model as well as a human breast cancer model.
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Fig. 1. Photosensitizer excitation. When the photosensitizer is exposed to light, the light
energy is absorbed and the photosensitizer is elevated to an excited state. The excited
photosensitizer is also able to reach a triplet state through intersystem crossing. From
there it can release energy through phosphorescence or can go on to create reactive
oxygen species.
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CHAPTER 2

EXPERIMENTAL PROCEDURES
Chemicals Used - Minimum Essential Medium (MEM), Dulbeceo’s Eagle Minimum
Essential Medium (DMEM), Fetal Bovine Serum (FBS), Phosphate Buffered Saline
(PBS), trypsin-EDTA and 0418 sulfate were purchased from Invitrogen, Ine (Carlsbad,
CA.) Buthionine-sulfoximine (BSO), a-toeopherol (vitamin E), 1,1,3,3Tetraethoxypropane (TEP), Ellman’s reagent (5,5-ditiosbis(2-nitro-benzoie acid)), 2thiobarbituric acid (TBA) and 5-aminolevulinic acid was purchased from Sigma (St.
Louis, MO.) Photofrin® was a generous gift from AXCAN Pharma, Inc (QC, Canada).
All reagents and enzymes used for flow cytometry were o f analytical grade from Sigma
(St. Louis, MO.) unless otherwise noted. The BODIPY C n (581/591) lipid oxidation
probe (#D-3861) was purchased from Molecular Probes, Invitrogen, Ine (Carlsbad, CA).
Bradford Assay Reagent (Coomassie Plus) was purchased from Pierce Biotechnology
(Rockford, IE).

Tissue Culture - Two model systems for cancer were used in these experiments. The first
system was a human breast cancer model system. There were four epithelial breast
cancer cell lines used. The DC4 and DB46 breast cancer cells were genetically
engineered from the parental line MDA-MB-231 as described by Carper et al (25).
M DA-MB-231 cells are a human epithelial breast adenocarcinoma. To maintain the
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integrity o f the transfection, the cells were grown in G418 sulfate. The MCF7 cells are a
human epithelial breast adenocarcinoma which is caspase 3 negative. The MCF7 cells
were obtained from American Type Culture Collection (ATCC), number HTB-22.
MDA-MB-435 cells are a human breast ductal carcinoma also obtained from ATCC,
number HTB-129.
The second model system used was a rat glioma model. Two rat glioma cell lines
were used. The F98 cells are an undifferentiated malignant glioma derived from a CD
Fisher rat fetus after exposure to ethyl-nitrosurea (ATCC). The BT 4 C cells are a glioma
model derived from a BD-IX rat after exposure to ethyl-nitrosurea (27). Both cell lines
were a generous gift from Dr. Steen Madsen.
MCF7, MDA-MB-435, DC4 and DB46 cells were grown in MEM supplemented
with 10% FBS, 50 mM HEPES buffer (pH 7.4), Penicillin (100 U/mL) and Streptomycin
(100 mg/mL). DC4 and DB46 cells were also grown in the presence o f G418 sulfate
(600 pg/mL). BT4C and F98 cells were grown in DMEM supplemented with 10% FBS,
50 mM HEPES buffer (pH 7.4), Penicillin (100 U/mL), and Streptomycin (100 mg/mL).
All cell lines were maintained at 37°C, 100% humidity and CO 2 / air (5%/95%)
atmosphere.

Vitamin E and BSO - The BSO stock was made at a concentration o f 5 mM in PBS.
Vitamin E was first dissolved in 95% ethanol and then diluted with PBS to a final
concentration o f 5 mM vitamin E in 25% ethanol. BSO and vitamin E were added to cell
media 24 hours prior to irradiation at a concentration o f 50 pM. When cells were washed

20

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

and re-suspended in media, free o f serum, with the photosensitizer, BSO or vitamin E
were added to the new media also (19,28).

Irradiation o f Cells - To perform PDT treatment on monolayered cells, a pretreatment o f
the photosensitizer is needed. A four hour pre-treatment with both ALA and Photofrin®
was used. A final concentration o f 1 mM o f ALA and 2.5 pg/mL o f Photofrin® was used
unless otherwise indicated. These concentrations were determined through literature
searches and empirical trials (29, 30). During pre-treatment, the cells were maintained in
serum free media (0% FBS) to facilitate uptake o f the photosensitizing agents into the
cells and to maintain intracellular concentrations.
A 100 mM stock solution o f ALA was prepared in 100 mM HEPES buffer (pH 7.5,
with NaOH). Photofrin® was obtained from Axcan Pharma in a dehydrated form that had
been normalized to a physiological pH by methods that were not disclosed. Photofrin®
was resuspended with PBS at a stock concentration o f 2.5 mg/mL in PBS.
Cells were seeded 48 hours prior to treatment, to obtain a non-confluent culture o f
dividing cells during treatment. To prepare the cells for pre-treatment, they were washed
once with 5 mL o f PBS and resuspended in 5 mL o f serum-free medium. The stock
solution o f the photosensitizer was added to the serum-ffee media, to obtain a final
concentration o f 1 mM ALA or 2.5 pg/mL Photofrin®. Cells were allowed to incubate
for four hours in the dark in a 37°C incubator. Following incubation, cells were
irradiated with 635 run light fi’om a diode laser (High Power Devices, North Brunswick,
NJ) at an irradiance o f 35 mW/cm^. Radiant exposures ranged from 0.5-20 J/em^ with
irradiation times ranging fi’om 14-571 seconds.
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Fluorescence Studies - Tumor cells were incubated with the photosensitizer and serumfree medium at variable concentrations and time in the manner described above. After
incubation, cells were washed with 5 mL o f PBS and harvested with trypsin. The cells
were re-suspended in 4 mL o f media (10% FBS). The cell suspension was centrifuged at
1000 g for 5 minutes. The cell pellet was then resuspended in 5 mL o f media.
Fluorescence intensity was evaluated using a FACS Calibur cytometer. Cells were
excited with a 488 nm laser and the fluorescence was measured using the FL-2 filter.
The mean fluorescence o f the total cell population was obtained after analyzing 2000
cells.

Clonogenic Survival - Clonogenic survival studies were done to identify the ability o f
ALA and Photofrin®-mediated PDT to inhibit cell proliferation. Following irradiation,
cells were washed with 5 mL o f PBS and harvested by trypsinization. After being
resuspended in media, the cells were counted with a Coulter counter. A known number
o f cells were plated into 60 mm dishes. Cells were allowed to grow for 11-14 days and
colonies containing more than 50 cells were counted by hand after staining with 0.5%
crystal violet in 95% ethanol. The average number o f colonies per 60 mm dish was 100.
The number o f colonies that formed in the experimental plates was normalized to the
control group (cells incubated with the photosensitizer, but receiving no light treatment).

Flow cytometry with Propidium Iodide - Propidium iodide (PI) will stain DNA, but is not
able to pass through an intact cellular membrane. PI is a fluorescent stain that is excited
in the blue region and emits a red color. By first treating cells with a detergent and then
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staining them with PI, we are able to quantify the amount o f DNA per cell. The phase o f
the cell cycle can be determined by quantifying the amount o f DNA. In the G1 phase o f
the cell cycle, the cells contain IN amount o f DNA. During the S phase, the cells are
actively synthesizing DNA and have between a IN and 2N amount o f DNA. In the G2
phase o f the cell cycle, the cell will contain a 2N amount o f DNA. Apoptotic vesicles are
classified by those containing less than IN DNA and being smaller in size than whole
cells.
Cells that were to be analyzed with PI for cell cycle distribution were washed with
5 mL o f PBS. They were then harvested using trypsin and centrifuged for 5 minutes at
1000 g. The cell pellet was resuspended in 5 mL o f PBS and the cells were centrifuged
again at 1000 g for 5 minutes. The cell pellet was resuspended in 100 pL o f PBS and
then 1 mL o f 70% ethanol at -20°C was added dropwise. The cell solution was stored at
4°C until the cells were analyzed. Ethanol-fixated cells were cleared o f excess fixative
by a single wash with 5 mL o f cold PBS and centrifuged at 500 g for 5 minutes. The
pellet was resuspended with 1.0% Triton X in PBS. A 1.0 mg/mL RNAse solution was
added and the mixture was incubated at room temperature for 10-15 minutes before
staining with 100 pg/mL PI solution. The final PI concentration in the test mixture was
50 pg/mL. Cytometry acquisition was done using the BD FACS Calibur with the argon
laser set at 488 nm on the linear Flow Channel 2 (FL-2) with Doublet Discriminatory
Module and Threshold set on FL-2. Modfit 3.0 was used to assign distribution curves to
data analyzed with PI and flow cytometry.
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Cell Attachment assay - To study the immediate effects o f PDT o f cancer cells, cell
attachment assays were performed within the first four hours after PDT treatment. Cells
were seeded into flasks 48 hours prior to irradiation at a concentration o f 200,000 cells
per flask. After irradiation cells were incubated at 37°C. After incubation a 100 pL
sample o f the media was counted using a Beckman culture counter. The remaining
media was discarded and the cells were washed with 5 mL o f PBS. The cells were
harvested using trypsin and a 100 pL sample o f the attached cells was counted using the
same culture counter. The total number o f cells (attached and floating) in the control
flask at time zero was used to normalize all other counts for that cell line.

Fluorescent Microscopy - To determine the amount o f apoptosis and necrosis o f the cells
after PDT treatment, fluorescent microscopy was used. Hoechst 33342 is a molecule that
stains DNA in apoptotic and necrotic cells. Hoechst stain is able to cross an intact
plasma membrane, but healthy cells are able to pump the stain back into the extracellular
space. Hoechst stain is a fluorescence dye that is excited in the UV region and emits a
blue color. PI stain is also used with fluorescent microscopy. PI is able to stain the DNA
of cells that do not have an intact cellular membrane. In order to characterize apoptotic
cells, Hoechst positive staining without PI positive staining must be present. Necrotic
cells are characterized by PI positive staining.
Approximately 10,000 cells per well were seeded on 4 chamber microscope slides,
48 hours prior to PDT treatment. Cells were irradiated as described above. After light
irradiation, cells were washed with PBS and allowed to incubate in MEM supplemented
with serum for a set period o f time (24-48 hours). After incubation cells were stained
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with 500 pL o f Hoechst 33342 (2 pg/mL) and 500 pL o f PI (10 pg/mL) for 15 minutes.
In three separate fields, pictures were taken o f the bright field, and then the same image
was photographed with UV and blue excitation filter using a photometries coolsnap CCD
digital camera attached to Nikon TE-200U inverted fluorescent phase contrast
microscope (Nikon, Ine. Melville, NY, USA). The total number o f cells were counted in
the bright field and this was compared to the number o f cells staining positive for each
dye. Cells staining positive for both Hoechst and PI were included only in the PI positive
counts.

Lipid peroxidation measurements with HPLC - Lipid peroxidation was measured as an
increase in intracellular MDA (31). MDA is the end product o f fatty acid oxidation. By
quantifying the amount o f MDA in the cell, the amount o f lipid peroxidation can be
deduced. MDA can be measured by formation o f an adduct with thiobarbutirie acid
(TBA). TBA binds with MDA in a 2:1 ratio, forming a colorimetric product that absorbs
at 532 nm (Fig. 7, page 29). To normalize the amount o f MDA to the total amount o f
protein per sample, a Bradford assay was performed to quantify the total protein content.
The standard used for this experiment was TEP. MDA is not stable in solution for long
periods o f time. TEP under high heat and acidic conditions will break down into MDA.
TEP is an ideal standard for the TBA:MDA analysis.
Cells were seeded (800,000 per flask) 48 hours prior to irradiation. After incubation
with the photosensitizer and prior to irradiation, the cells were washed with 5 mL o f PBS
and then resuspended in 2.5 mL o f PBS. The cells were irradiated as described above.
After irradiation the cells were scraped from the flask and a cell pellet was obtained by
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centrifugation at 1000 g for 5 minutes. The pellet was resuspended in 0.75 mL o f a 0.9%
NaCl solution. The cells were then lysed open by freeze/thawing. There were two cycles
of 20 minutes at -80°C followed by 5 minutes at 37°C. After lysing, 10 pL o f the lysate
was saved for protein quantification with Bradford reagent. To 650 pL o f the remaining
cell lysate, 250 pL o f a 20% trichloraeetie acid solution was added to precipitate the
proteins. After a 10 minute incubation, 200 pL o f a 0.67% solution o f TBA was added
and the sample was heated to 100°C for 20 minutes. After, heating the sample was
centrifuged for 5 minutes at 12,000 rpm and a clear pink solution was obtained. Then 10
pL o f this sample was then injected into the Water Seperation Module 2695 HPLC. The
samples were run at a 40% MeOH:60% 0.5 M Ammonium Acetate solution (pH 5.5) on a
C l 8 column using a flow rate o f 1 mL/min. The absorbance was measured to the linked
Photodiode array 2996. The TBA:MDA adduct was measured as a peak at approximately
2 minutes at 532 nm. The area o f the peak was quantified by Empower software (Waters,
Milford, MA). The amount o f MDA per sample was normalized to total protein content.

Protein oxidation using Ellman ’s Reagent - There are many targets o f oxidation in
protein molecules. The thiol group o f the amino acid cysteine is easily oxidized. The
measurement of reduced thiol groups can be done using Ellman’s reagent (32). As the
cysteine residues are oxidized, the amount o f reduced thiol groups is decreased. Ellman’s
reagent forms an adduct with reduced cysteine residues (Fig. 8 , page 30). The by-product
o f this reaction is a thiol anion which absorbs at 405 nm. As cysteine residues are
oxidized, the loss o f color product is expected.
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Cells were seeded 48 hours prior to irradiation at a concentration o f 250,000 cells
per flask. In order to measure thiol groups using Ellman’s reagent the cells were
incubated with the photosensitizer as described above and prior to irradiation were
washed with 5 mL o f PBS and then covered in 1 mL o f PBS. After the cells were
irradiated, they were immediately placed in ice. The cells were scraped from the flasks
and then were lysed by a freeze/thaw cycle. There were two cycles o f 20 minutes at
-80°C followed by 5 minutes at 37°C. After lysing, the cells were centrifuged for 5
minutes at 1000 g to pellet whole cells and large membrane fragments. The supernatant
was then analyzed using a 0.04% solution o f Ellman’s reagent (DNTB) in a 0.1 M tris
buffer (pH 8.0). In a 96 well plate, 40 pL o f cell lysate, 40 pL o f a 0.1 M tris buffer
containing 0.1 M glycine and 4 M EDTA (pH 8.0) and 10 pL o f Ellman’s reagent were
mixed. After incubating for 10 minutes at 37°C, the sample was measured using a Tecan
plate reader at 405 nm. This measurement was then normalized to the total amount o f
protein in the sample as quantified with Bradford reagent.

Oxidative Sensitive Lipid Probe - The BODIPY 581/591 C u probe (4,4-diflouro-5-(4phenyl-l,3-butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-undecanoic acid) is a fatty acid
analog that can be incorporated in cells. Before oxidation the probe has a red
fluorescence (590 nm) when excited with a green light (530 nm). After oxidation the
BODIPY probe has green fluorescence (535 nm) when excited with a blue light (485
nm). Using this probe we can visualize the location o f oxidation within the cell and also
measure the amount o f lipid oxidation.
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The BODIPY probe was first dissolved in DMSO and then MEM was added to a
final concentration o f 200 pM in 50% DMSO. Cells analyzed by fluorescent microscopy
were seeded into welled slides at a concentration o f 10,000 cells per well 48 hours prior
to irradiation. After 4 hours incubation with the photosensitizer, the probe was added to
the media at a final concentration o f 10 pM. After a 15 minute incubation with the probe,
the media was removed and PBS was added. The cells were irradiated and immediately
after irradiation the cells were analyzed. Fluorescent microscopy pictures were taken
after the chambers were removed from the slide and cover slips were placed over the
cells. A lOOX objective was used with a green filter to capture the red fluorescence
pictures.

Statistical Analysis - Graph Pad Prism 4.0 (Graph Pad Software, San Diego, CA) was
used to graph and run non-linear regressions on data. Graph Pad Quick Calcs
(www.graphpad.com) was used for student’s t test. P values less than 0.05 were
considered significant. All graphical error bars are representative o f standard error
measurements.
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CHAPTER 3

RESULTS
PDT is a two step treatment modality. Individually the photosensitizer or the light
was not effective in killing tumor cells. ALA and Photofrin® toxicity was analyzed using
the MDA-MB-435 cells (Fig. 9, page 46). Clonogenic survivals were conducted with
both photosensitizers in the absence o f light. ALA did not show a decrease in survival
until 10 times the amount used in our PDT studies (10 mM). Photofrin® showed no
toxicity at concentrations ranging from 0-15 pg/mL. The effect o f the laser on the breast
cancer cells was also studied (Fig. 10, page 47). The application o f laser light alone did
not show any significant dose effects on the MCF7 or MDA-MB-435 cells between 0 and
20 J/cm^. This confirms that in order for PDT to be effective in killing tumor cells that
both a light source and the photosensitizer must be present.
To better understand the effectiveness o f PDT-induced cell death, clonogenic
survivals were performed. ALA-mediated PDT was studied with all four breast cancer
cell lines and the two glioma lines. Photofrin®-mediated PDT effectiveness was also
assessed with the four breast cancer cell lines. All tumor lines exhibited a dose
dependent response to PDT treatment. MDA-MB-435 cells were treated with ALAmediated PDT and showed an LC 5 0 o f 2.2 J/cm^ (Fig. 11, page 48). The MDA-MB-435
cells reached an LC 9 0 around 4 J/cm^. The DB46 cells had sensitivity similar to that o f
ALA-mediated PDT and had an LC 5 0 o f 2.7 J/cm^(Fig. 12, page 49). Unlike the MDA-
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MB-435 cells, the DB46 cells did not reach an EC 9 0 until a dose o f 8 J/cm^. The DC4
cells, which differ from the DB46 by lower levels o f hsp27, were more sensitive than
both the MDA-MB-435 and DB46 with an EC 5 0 value o f 1.7 J/cm^ (Fig. 13, page 50). At
4 J/cm^, the DC4 cells reach an EC 9 0 . The MCF7 cells were the most sensitive breast
cancer cell line among those studied to ALA-mediated PDT (Fig. 14, page 51). The LC 5 0
value for MCF7 cells was 0.4 J/cm^ and an LC 9 0 was reached before 2 J/cm^ dose.
The two glioma lines studied were less sensitive to ALA-mediated PDT as
compared to the breast cancer lines with the glioma LC 5 0 values being approximately 5
J/cm^ greater than those o f the breast cancer cells. This effect could be contributed to
either a tissue or species difference. The F98 cells exhibited an EC 5 0 value o f 4.4 J/cm^
(Fig. 15, page 52). At a dose o f 20 J/cm^the survival was still approximately 20%. The
BT 4 C were the least sensitive o f the cell lines investigated with an LC 5 0 o f 7.3 J/cm^ (Fig.
16, page 53). There was 17% survival at the highest dose investigated (20 J/cm^).
Neither the F98 or the BT4C cells reached an LC 9 0 by 20 J/cm^.
Photofrin®-mediated PDT efficacy was also investigated by clonogenic survival.
MDA-MB-435 cells were treated with Photofrin®-mediated PDT and a clonogenic
survival assay was performed (Fig. 17, page 54). The LC50 value o f the MDA-MB-435
cells treated with Photofiin®-mediated PDT was 0.7 J/cm^. The MDA-MB-435 cells
reached an LC90 at 2 J/cm^. The DB46 cells had similar sensitivity to Photofrin®mediated PDT as the MDA-MB-435 cells (Fig. 18, page 55). The LC50 value was the
same as the MDA-MB-435 cells at 0.7 J/cm^. The LC90 for the DB46 cells was around 2
J/cm^. The DC4 cells were slightly less sensitive to Photofrin®-mediated PDT than the
DB46 cells (Fig. 19, page 56). The DC4 cells also reached an LC90 at 2 J/cm^. The DC4
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cells have an EC 5 0 value of 0.8 J/cm^. The MCF7 cells were again the most sensitive o f
the cell lines to Photofrin®-mediated PDT with an EC 5 0 value o f 0.4 J/cm^. The MCF7
cells reached an EC 9 0 value 1 J/cm^. Table I (page 58) summarizes EC 5 0 values o f all cell
lines and PDT treatments investigated. The errors can be estimated by looking at the
individual

values o f the non-linear regression lines on each graph. BT 4 C and F98 cells

were not investigated with Photofrin®-mediated PDT.
Flow cytometry analysis o f the cell cycle distribution was performed on the four
breast cancer lines with both ALA and Photoffin®-mediated PDT to confirm results seen
with clonogenic survival assays. Approximately 2000 cells were analyzed per data point.
As seen in Fig. 21 (page 59) the cells are graphically represented in a histogram format
by the amount o f DNA per each cell as quantified with PI. Modfit 3.0 was used to
analyze the histogram and fit a standard curve to the data resented. The percent o f cells
per stage o f the cell cycle is reported. As shown, the apoptosis peak, that is located preG l, increases as the dose o f PDT increases. The data shown is typical o f the data
analyzed with all cell lines with both ALA and Photoffin®-mediated PDT.
MDA-MB-435 cells were analyzed with flow cytometry and the data is shown in
Table II (page 60). Cells were harvested both at 24 and 48 hours post irradiation. The
result from a single experiment is shown which is representative o f both experiments.
With ALA-mediated PDT, at the 24 hour time point the apoptosis peak increase as the
light dose increases. This same trend is seen at the 48 hour time point, with the apoptosis
peak increasing as the dose o f ALA-mediated PDT. The 48 hour peaks are increased
from the 24 peaks at the same dose. With ALA-mediated PDT there is no trend in the
G I, S or G2 peak with dose. Photofrin®-mediated PDT was also investigated. There
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was again a dose response effect observed with the apoptosis peak increasing with
increasing dose both at the 24 and 48 hour time points. There is no observable difference
between the 24 hour and 48 hour time points in the apoptosis peaks. There is also a trend
in the decrease o f the S peak in both the 24 and 48 hour time points.
The DB46 cells were also analyzed with flow cytometry at 24 and 48 hour time
points (Table III, page 61). With ALA-mediated PDT, the DB46 cells showed a much
lower dose dependent trend than the MDA-MD-435 cells with only 27% apoptosis as
compared to 56% in the MDA-MB-435 cells. At the 24 time point the 4 J/cm^ and the 20
J/cm^ apoptosis peaks are similar at approximately 16%. At the 48 hour time point there
is not a dose response until the 20 J/cm^ dose. There is no discernible trend in the G l, S
or G2 peak in either the 24 or 48 hour time point with the ALA-mediated PDT cells.
With Photofrin®-mediated PDT the DB46 cells again show a dose dependent trend with
an increase in the apoptosis peak with an increase in dose at both 24 and 48 hour time
points. The 24 and 48 hour time points again have very similar apoptosis peaks. The
same trends are observed in the MDA-MB-435 cells where the S peak decreases as the
dose o f Photoffin®-mediated PDT increases.
The DC4 and MCF7 cells were also analyzed with flow cytometry with ALA and
Photofrin®-mediated PDT (Table IV and Table V, pages 62-63). We see similar trends
that were observed with the DB46 and MDA-MB 435 cells. Both time points and with
both ALA and Photoffin®-mediated PDT there is a dose dependent response with an
increase in the apoptosis peak. The DC4, 48 hour time point with Photoffin®-mediated
PDT there is not a decrease in the S peak. Also in the MCF7 cells, at the 24 hour time
point with Photofiin®-mediated PDT the S peak does not show a significant increase.
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PpIX and Photofrin® have an inherent fluorescence. This property can be
exploited to estimate the comparative concentration o f photosensitizer within the cell.
Fluorescent value o f tumor cells after incubation with ALA or Photofrin® was quantified
with the flow cytometer. Varying the concentration and the time o f incubation with the
photosensitizer was investigated. ALA concentrations were varied between 0 and 2.5
mM o f ALA with an incubation time o f four hours (Fig. 22A, page 64). All values were
normalized to the zero point (data not shown). The MCF7 cells showed the highest
amount of fluorescence o f the cell lines investigated with a mean fluorescence per cell o f
101 a.u. at 2.5 mM ALA. The MDA-MB-435 cells were the least fluorescent with a peak
fluorescence per cell o f 43 a.u. at 0.5 mM o f ALA.

All cell lines, DC4, DB46, MCF7,

MDA-MB-435 and BT 4 C, reached a maximum fluorescence at approximately ImM o f
ALA. Photofrin® concentrations were varied between 0 and 10 pg/mL with a four hour
incubation (Fig. 22B, page 64). With the four cell lines investigated, MCF7, DC4, DB46
and MDA-MB-435, there was a dose dependent response with the increase o f
fluorescence per cell increasing with concentration o f Photofrin®. The DB46 cells
exhibited the highest fluorescence per cell with a peak fluorescence at 10 pg/mL o f
Photofrin® o f 3700 a.u. The MDA-MB-435 cells were the least responsive to Photofrin®
with a peak fluorescence per cell o f 680 a.u. at 10 pg/mL o f Photofrin®.
The incubation time o f both ALA and Photofrin® was also investigated. Tumor
cells were incubated with ImM ALA for 0-5 hours (Fig 23 A, page 65). The MCF7 cells,
again, had the highest fluorescent values o f the cell lines investigated and had a peak
fluorescence o f 585 a.u. at 4 hours. The MDA-MB-435 cells reached a plateau o f
fluorescence at 3 hours o f 63 a.u. per cell. The DB46 cells reached a plateau earlier at I
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hour o f 110 a.u. per cell. The DC4 cells exhibited an increase o f fluorescence at every
time point with a peak fluorescence per cell o f 218 a.u. at five hours. The BT 4 C cells
also had a dose dependent response with time. The BT 4 C peak fluorescence was 102 a.u.
at five hours. Photofrin® incubation was done at a concentration o f 2.5 pg/mL with the
same time frame o f 0-5 hours (Fig. 23B, page 65). With Photofrin® incubation all cell
lines exhibited a dose response with respect to time. The DB46 cells exhibited the
highest fluorescent response with the DC4 cells being not significantly different at the
highest fluorescent amount (p > 0.5). The DB46 fluorescent at five hours was 1000 a.u.
per cell. The MDA-MB-435 cells were again the least fluorescent o f the cell lines
investigated with a peak fluorescence o f 360 a.u. per cell at five hours.
Cell attachment assays were performed to investigate the immediate effects o f
PDT treatment. Attached and floating cells were quantified at two and four hours after
PDT treatment. MDA-MB-435 cells were analyzed at 2 and 10 J/cm^ dose o f ALAmediated PDT (Fig. 24, page

6 6

). The 2 J/cm^ dose did not affect the attached cells as

compared to the control flasks. The 2 J/cm^ dose did increase the amount o f cells
floating in the media by a very small amount. The 10 J/cm^ dose caused an increased
detachment o f approximately 40% at the 4 hour time point, as confirmed in both the
attached cells and the floating cells. It is interesting to speculate if at time points greater
than 4 hours the number o f cells detaching would continue to increase.
The attachment assay was also performed on MDA-MB-435 cells treated with
Photofrin®-mediated PDT (Fig. 25, page 67). These results differed from the ALAmediated PDT response. The 2 J/cm^ dose appeared to be causing the detachment o f
more cells than the higher dose o f 10 J/cm^. This assay was performed two times with

36

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

the same increased 2 J/cm^ effect happening in both trials. At the four hour time point,
with the 2 J/cm^ dose, there is a decrease in attached cells o f approximately 55% with an
increase in floating cells o f 35%. This may indicate that there is a loss o f 20% o f the
cells due to necrosis. Also at the four hour time point, with the 10 J/cm^ dose, there is a
decrease in attached cells o f 30% with an increase in floating cells o f 40%. This does not
make biological sense and warrants further investigation.
The rat glioma line, BT4C cells were also analyzed with an attachment assay after
treatment with ALA-mediated PDT (Fig. 26, page

6 8

). BT4C cells display a similar

effect that was observed with the MDA-MB-435 cells. The detachment o f cells is dose
dependent and seems to have similar values at the two hour and four hour time point.
The 10 J/cm^ dose had a detachment o f 30% with an increase in the floating cells o f 5%
at the four hour time point. This may again point to some loss o f cells due to necrosis,
but is not definitive. The 2 J/cm^ dose had a smaller effect with the detachment o f 10%
o f the cells and an increase in the floating cells o f less than 5% at the four hour time
point.
Fluorescent microscopy analysis was used to determine the amount o f necrosis
and apoptosis after PDT treatment. Four cell lines were investigated using ALAmediated PDT 24 hours after treatment (Fig. 27, page 69). Apoptosis was measured by
using Hoechst stain 33342 and normalizing the number o f positive cells to the total
number o f cells in the bright field image (Fig. 27A, page 69). The amount o f apoptosis
that was observed was low (less than 25%), but did exhibit a dose dependent trend. The
two brain cell lines, BT 4 C and F98, exhibited higher amounts o f apoptosis than the two
breast cancer cell lines, MCF7 and MDA-MB-435. The F98 cells had the highest amount
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o f apoptosis, 22% at 10 J/cm^. The MCF7 cells were very similar to the MDA-MB-435
cells and had the lowest amount o f apoptosis, 5% at the 10 J/cm^ dose. Necrosis was also
measured using PI stain and normalizing the number o f positive cells to the total number
o f cells in the bright field image (Fig. 27B, page 69). In all cell lines necrosis was dose
dependent. The MDA-MB-435 cells had the highest amount o f necrosis with 17% o f the
cells being necrotic. The BT4C cells had the lowest amount o f necrosis with less than 2%
necrotic cells at the 10 J/cm^ dose.
Fluorescent microscopy was also used to study the timeline o f events after PDT
treatment in the MDA-MB-43 cells (Fig. 28, page 70). ALA mediated-PDT was
performed on MDA-MB-435 cells at 0, 2, 4 ,1 0 and 20 J/cm^ and microscopy images
were obtained after both 24 and 48 hours (Fig. 28A, page 70). At the 2 and 4 J/em^ dose
there is very little difference between the 24 and 48 hour time points. Both the apoptotie
and necrotic values are less than 5% at both the 24 and 48 hour time point for 2 and 4
J/cm^. At the 10 J/cm^ dose there is an increase in the necrotic value and a decrease in
the apoptotic value between the 24 hour and 48 hour time points. This might be
indicating a shift from early to late apoptosis, since PI can also be indicative o f late
apoptotic events. At the 20 J/cm^ dose there is a large decrease in the necrotic cells
between the 24 and 48 hour time points. This might be indicative o f the rupture o f
necrotic cells and the loss of total cell number between 24 and 48 hours.
Photofrin®-mediated PDT was also analyzed for a time course with fluorescent
microscopy with MDA-MB-435 cells (Fig. 28B, page 70). In the Photofiin® treated cells
there is a general decrease in necrotic cells and an increase in apoptotic cells between the
24 and 48 hour time points. At 24 hours, there is a large amount o f necrosis present that
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is dose dependent, with very little apoptosis. At the 48 hour time point the necrosis
amounts have decreased and there is evidence o f apoptosis at 2 and 4 J/cm^, between 5
and 10%. At 48 hours there is still a dose response o f increased cell death with increased
dose o f Photoff in®-mediated PDT.
Oxidation is an important indicator o f cell cytotoxicity with PDT treatments.
Loss of reduced thiol groups was measured as an indicator o f protein oxidation. Four cell
lines were analyzed for protein oxidation with ALA-mediated PDT (Fig. 29, page 71). In
all four cell lines, MDA-MB-435, MCF7, F98 and BT4C, there was protein oxidation
after ALA-mediated PDT treatment. There was not a strong dose dependent trend with
the amount o f oxidation and the dose o f ALA-mediated PDT. The differences between
the 2 J/cm^ and 10 J/cm^ amounts o f protein oxidation were very little in all four cell
lines. The brain cancer cell lines, BT4C and F98, had a lower amount o f protein
oxidation than the breast cancer cell lines, MCF7 and MDA-MB-435. The MDA-MB435 cells had the largest amount o f oxidation at approximately 60% oxidation at 10
J/cm^. The F98 cells had the least amount o f protein oxidation with less than 10%
oxidized at 10 J/cm^.
Protein oxidation was also analyzed with the MDA-MB-435 cells with both ALA
and Photoffin®-mediated PDT (Fig. 30, page 72). To compare oxidation amounts at
equal survival levels, the protein oxidation was analyzed at the LC50 values o f MDA-MB435 with both ALA and Photofrin® treated cells. Also an LC90 value for each
photosensitizer was analyzed. These values were 0, 0.5 and 2 J/cm^ for Photofiin®mediated PDT and 0, 2.5 and 4 J/cm^ for ALA-mediated PDT. BSO and vitamin L were
used to modulate the amount o f anti-oxidants within the cell. With ALA treated MDA-
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MB-435 cells there was no differenee in protein oxidation between the 2.5 and 4J/cm^
(Fig. 30A, page 72). Interestingly the only significant difference that BSO and vitamin E
played with the ALA-mediated PDT was that BSO slightly inereased the amount o f
oxidation at the 4 J/em^ dose. This is expected as BSO will deerease the amount o f GSH
within the cell. All treatment groups had approximately a 50% oxidation level. The
Photofrin® treated eells showed a dose response with inereased oxidation as dose
increased (Fig. 30B, page 72). BSO did not signifieantly ehange the oxidation levels
with Photofrin®-mediated PDT, but vitamin E did increase the amount o f oxidation that
occurred. The vitamin E treated eells had the highest amount o f oxidation at 2 J/cm^ at
approximately 50% oxidized. If protein oxidation was eorrelative o f survival in PDT
treatment we would expeet to see similar oxidation levels at similar survival levels. This
is not the ease in comparing the ALA treated cells to the Photofrin® treated cells. The
Photofrin® treated eells have a lower amount o f oxidation at the EC50 values. At the EC90
values the Photofrin® and ALA treated eells do have similar protein oxidation levels.
In a comparison o f similar doses o f ALA and Photofiin®-mediated PDT, protein
oxidation still does not exhibit a strong dose dependents (Fig. 31, page 73). Photofrin®
has lower amounts o f oxidation at 2 and 20 J/cm^. There is a significant difference o f
approximately 20% between both the ALA and Photofrin®-mediated PDT cells between
the 2 and 20 J/cm^. The 4 J/cm^ Photofrin®-mediated PDT dose may not be
representative, sinee it is lower than both the 2 and 10 J/em^ dose.
Lipid peroxidation was analyzed to understand its role in eytotoxieity o f MDAMB-435 eells to ALA and Photofrin®-mediated PDT (Fig. 32, page 74). Lipid oxidation
was quantified by measuring the amount o f MDA with HPLC analysis using a

40

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

photodiode array. The ALA-mediated PDT treated cells showed a higher amount o f lipid
peroxidation at all doses. There was not a significant increase in lipid peroxidation until
the 4 J/em^ dose in the ALA treated cells. The 10 and 20 J/cm^ dose was similar at 0.003
pM /pg o f MDA per protein in the ALA treated eells. The Photofrin® treated cells did not
have a significant increase in lipid peroxidation until the 20 J/cm^ dose (p > 0.05). This
data suggests that bulk lipid peroxidation is not the only factor that plays a role in PDT
eytotoxieity since there is a less than 10% cell survival o f Photofrin® treated cells after a
4 J/cm^ dose.
To better understand the effeets o f oxidation on eytotoxieity, BSO and vitamin E
were used to modulate the levels o f anti-oxidants within the cell. Fluorescent microscopy
was used to analyze the effects o f BSO and vitamin E on apoptosis and necrosis in MDAMB-435 cells 24 hours after irradiation (Fig. 33A, page 75). Vitamin E had little effect
on apoptosis or necrosis as compared to the ALA-mediated PDT treated control cells.
With both the ALA treated cells and the ALA with vitamin E treated cells there was
approximately 85% neerosis. The BSO treatment had two different effeets on the MDAMB-435 treated eells. At 0, 2 and 4 J/cm^ it greatly inereased the amount o f necrosis and
decreased the amount o f apoptosis. This trend did not continue and at 20 J/em^ the BSO
treated eells had lower amounts o f neerosis. The Photofrin®-mediated PDT eells also
were treated with BSO and vitamin E and analyzed with fluorescent mieroseopy (Fig.
33B, page 75). In all the Photofrin® treated MDA-MB-435 eells there was very little or
no apoptosis present. At 2 J/em^, vitamin E proteeted the eells from neerosis by about
35%. At the same dose o f 2 J/cm^, the BSO may have sensitized the cells to the
Photofrin® treatment. At 20 J/cm^ the BSO treatment sensitized the cells by eausing 12%
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more necrosis. With the Photofrin -mediated PDT, the effects seen with BSO and
vitamin E are at low doses and in small quantities.
Clonogenic survivals were also performed with BSO and vitamin E on the breast
eancer cell lines to understand the role o f anti-oxidants in ALA-mediated PDT treatment.
MDA-MB-435 cells responded to vitamin E and BSO as expected (Fig. 34, page 76). All
three groups responded in a dose dependent manner. Vitamin E provided protection
against ALA-mediated PDT at 1, 2.5 and 4 J/em^. BSO treatment o f cells resulted in less
clonogenie survival at 1 and 2.5 J/cm^. At 10 J/cm^ the ALA treatment, BSO and vitamin
E treatment were similar at less than 5% survival. The DB46 cells did not have the
expected result when treated with BSO and vitamin E (Fig. 35, page 77). The vitamin E
treatment provided significant protection at all doses investigated between

0

and

2 0

J/cm^. The BSO also protected the ALA treated DB46 cells at the 2 J/em^ dose, resulting
in approximately 100% survival. At all other doses the BSO treatment did not seem to
affect the ALA-mediated PDT survival response. The DC4 cells had an expected
response to the BSO and vitamin E treatment (Fig. 36, page 78). The vitamin E provided
protection to the ALA treated DC4 cells at 2 and 4 J/cm^. The BSO also decreased the
survival at 2 and 4 J/em^. At 8 , 10 and 20 J/cm^ there was less than 6 % survival in the
ALA, BSO and vitamin E treated eells. The MCF7 eells were exposed to ALA-mediated
PDT, treated with BSO and had an increased sensitivity o f 5% compared to controls at 2
J/cm^ (Fig. 37, page 79). Vitamin E proteeted the MCF7 cells by inereasing the survival
by

1 0

% as compared to the eontrol group.
The role o f vitamin E and BSO were also investigated with Photofrin®-mediated

PDT MDA-MB-435 cells (Fig. 38, page 80). The no addition, BSO and vitamin E
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groups respond in a dose dependent manner to the Photofrin -mediated PDT. At the 0.5
J/em^ dose, there is lowered survival with the addition o f BSO to the cells, but at 2 J/em^
the BSO treatment aetually provides a signifieantly small amount o f proteetion to the
MDA-MB-435 eells. At 2 J/cm^, vitamin E does provide proteetion to the eells against
Photofrin®-mediated PDT eytotoxieity. At 4 and 10 J/cm^ there is no significant
difference between the no addition, BSO and vitamin E groups. Vitamin E was also
shown to provide protection to DC4 cells against Photofrin®-mediated PDT (Fig. 39,
page 81). At 2 and 4 J/em^ vitamin E provides significant protection against Photofnn®mediated PDT. At 20 J/cm^ there is no protection seen for vitamin E.
Vitamin E has been reported to both protect and sensitize cells to Photofrin®mediated PDT. To investigate these effects further flow cytometry analysis was
performed on DC4 cells treated with Photofrin®-mediated PDT and vitamin E (Fig. 40A,
page 82). At the 24 hour point vitamin E has an increased apoptosis peak at 4 J/em^ as
compared to the Photofrin® treated sample, but at 2 and 20 J/cm^ there is a slight
protective effect that vitamin E is exhibiting. At the 48 hour time point, at all doses
investigated, vitamin E treated cells display more apoptosis than the Photofrin® treated
cells. At both the 24 and 48 hour time points the cells responded in a dose dependent
manner with increased apoptosis peaks at higher doses. DB46 cells were also analyzed
using flow eytometry with Photofrin®-mediated PDT and vitamin E (Fig. 40B, page 82).
The DB46 cells display similar trends to the DC4 eells. At the 24 hour time point,
vitamin E has similar apoptosis peaks at the 2 and 4 J/cm^ doses and a slightly lower peak
at the 20 J/cm^ dose. At the 48 hour time point, vitamin E has a much higher apoptosis
peak than the Photofrin® treated cells at the 2 and 20 J/cm^ dose, but has a lower peak at
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the 4 J/em^ dose. From this data, it may be concluded that vitamin E was not having a
protective effect against Photofirin®-mediated PDT and may be sensitizing cells in some
way to Photoffin®-mediated PDT.
To investigate the effeet that vitamin E has on breast caneer eells with Photofrin®,
the uptake o f Photofrin® into the cell was investigated (Fig. 41, page 83). Both
Photofrin® and vitamin E are lipophillic molecules. Perhaps vitamin E may be
facilitating the uptake o f Photofrin® into the eell. By measuring Photofrin® fluorescenee,
it was determined that vitamin E did not have any effect on the amount o f uptake o f
Photofrin® into the cell. The amount o f fluoreseence with Photofrin® alone and
Photofrin® with vitamin E was not different.
The localization o f the oxidative stress o f ALA and Photofrin®-mediated PDT
was investigated. The lipid oxidative probe, BODIPY C n , was utilized with fluorescent
mieroseopy. This was done to identify the intraeellular loealization o f the oxidative
stress. BT 4 C eells were incubated with the oxidative probe and treated with ALAmediated PDT (Fig. 42, page 84). When looking at the fluoreseent images we see a
general shift from red to green, confirming the oxidation o f lipids is observed. In the 4
J/em^ image, there are areas o f red and green, but it is unclear as to the intracellular areas
involved (Fig. 42D, page 84). In the 10 J/cm^ image, everything appears to be green
fluoreseent, signifying that both the eellular membrane and intraeellular organelles have
been oxidized (Fig. 42F, page 84). The MCF7 cells have a very similar pattern after
ALA-mediated PDT treatment (Fig. 43, page 85). In the 4 J/cm^ fluorescent picture there
appears to be a very punctuate pattern o f oxidation, but without a secondary stain it is
unclear as to the identification o f the organelles involved (Fig. 43D, page 85). The 10
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J/cm^ fluorescent image, again shows cells that are completely green, indicating that both
the cellular membrane and intracellular membranes were oxidized (Fig. 43F, page 85).
The MDA-MB-435 cells do not show the expected pattern o f red to green fluorescence as
inereased doses o f ALA-mediated PDT oeeurred (Fig. 44, page 86). The 4 J/em^ image
is much greener than the 10 J/cm^ image (Fig 44D and 44F, page 86). There is also a
punctuate pattern in the 10 J/em^ fluorescent image. The MDA-MB-435 cells were also
analyzed after Photoffin®-mediated PDT (Fig. 45, page 87). In this set o f images it is
easy to see the red to green shift as oxidation occurs. In the 10 J/cm^ image, everything
within the eell appears green (Fig. 45F, page 87). Unfortunately, without a secondary
stain, this data is inconclusive as to the target o f oxidation within the eell. A secondary
probe and confocal microscopy would be needed to better identify the localization affects
within the eell. Lower doses o f PDT may also be helpful in identifying any intracellular
targets.
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Fig. 9. Clonogenic survival o f MDA-MB-435 without light. Photosensitizers alone do
not cause toxicity at experimental doses. Clonogenic survival o f MDA-MB-435 cells
with photosensitizers without light irradiation was performed. Vertical line represents the
doses o f photosensitizers used in ALA (A) and Photofrin® (B) mediated PDT
experiments. Graph shown is a combination o f two experiments. In each experiment,
each data point was done in triplicate. Values were normalized to the 0 point, which did
not receive any photosensitizer.
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Fig. 10. Clonogenic survival o f tumor cells exposed to light. Light irradiation alone does
not cause toxicity at experimental doses. Clonogenic survival o f MDA-MB-435 and
MCF7 cells was performed with light irradiation, but without photosensitizers. Graph
shown is a combination o f two experiments. In each experiment, each data point was
done in triplicate. Values were normalized to the 0 point, which did not receive any light
irradiation.
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Fig. 11. Clonogenic survival o f MDA-MB-435 cells with ALA-mediated PDT. Non
linear regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location
o f the EC50 for the MDA-MB-435 cells with ALA-mediated PDT. EC50 = 2.2 J/cm^
Graph shown is a combination o f five experiments. In each experiment, each data point
was done in triplicate. R^=0.9925 for the non-linear regression.
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Fig. 12. Clonogenic survival o f DB46 cells with ALA-mediated PDT. Non-linear
regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location o f the
ECso for the DB46 cells with ALA-mediated PDT. EC 5 0 = 2.7 J/cm^ Graph shown is a
combination o f four experiments. In each experiment, each data point was done in
triplicate. R^=0.9725 for the non-linear regression.
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Fig. 13. Clonogenic survival o f DC 4 cells with ALA-mediated PDT. Non-linear
regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location o f the
ECso for the D C 4 cells with ALA-mediated PDT. ECso = 1.7 J/cm^ Graph shown is a
combination o f four experiments. In each experiment, each data point was done in
triplicate. R^=0.9974 for the non-linear regression.
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Fig. 14. Clonogenic survival o f MCF7 cells with ALA-mediated PDT. Non-linear
regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location o f the
ECso for the MCF7 cells with ALA-mediated PDT. ECso = 0.4 J/cm^ Graph shown is a
combination o f four experiments. In each experiment, each data point was done in
triplicate. R^-0.9738 for the non-linear regression.
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Fig. 15. Clonogenic survival o f F98 cells with ALA-mediated PDT. Non-linear
regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location o f the
ECso for the F98 cells with ALA-mediated PDT. ECso - 4.4 J/cm^ Graph shown is a
combination o f two experiments. In each experiment, each data point was done in
triplicate. R^=0.9040 for the non-linear regression.
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Fig. 16. Clonogenic survival o f BT4C cells with ALA-mediated PDT. Non-linear
regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location o f the
ECso for the BT 4 C cells with ALA-mediated PDT. ECso = 7.3 J/cm^ Graph shown is a
combination o f two experiments. In each experiment, each data point was done in
triplicate. R^=0.9477 for the non-linear regression.
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Fig. 17. Clonogenic survival o f MDA-MB-435 cells with Photofrin®-mediated PDT.
Non-linear regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the
location o f the ECso for the MDA-MB-435 cells with Photofrin®-mediated PDT. ECso 0.7 J/cm^ Graph shown is a combination o f four experiments. In each experiment, each
data point was done in triplicate. R^=0.9755 for the non-linear regression.
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Fig. 18. Clonogenic survival o f DB46 cells with Photofrin®-mediated PDT. Non-linear
regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location o f the
ECso for the DB46 cells with Photofrin®-mediated PDT. ECso = 0.7 J/cm^ Graph shown
is a combination o f three experiments. In each experiment, each data point was done in
triplicate. R^=0.9814 for the non-linear regression.
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Fig. 19. Clonogenic survival o f DC4 cells with Photofrin®-mediated PDT. Non-linear
regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location o f the
ECso for the DC4 cells with Photofrin®-mediated PDT. ECso = 0 .8 J/cm^ Graph shown
is a combination o f five experiments. In each experiment, each data point was done in
triplicate. R^=0.9896 for the non-linear regression.
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Fig. 20. Clonogenic survival o f MCF7 cells with Photoffin®-mediated PDT. Non-linear
regression fit by Graph Pad Prism 4.0 software. Vertical line signifies the location o f the
ECso for the MCF7 cells with Photofrin®-mediated PDT. ECso = 0.4 J/cm^ Graph shown
is a combination o f two experiments. In each experiment, each data point was done in
triplicate. R^=0.9981 for the non-linear regression.
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Cell Line
MDA-MD-435
DB46
DC4
MCF7
F98
BT4C

Table I
Calculated ECso values for PDT (J/cm^)
ALA-mediated PDT
Photofrin®-mediated
Cell Type
PDT
2.2
Breast
0.7
2.7
Breast
0.7
1.7
Breast
0.8
0.4
Breast
0.4
Glioma
4.4
nd
Glioma
7.3
nd

nd = not determined
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Fig. 21. Flow cytometry o f DC4 cells after ALA-mediated PDT. Cells were treated with
ALA-mediated PDT and 24 hours later were fixed for staining with PL Data is
representative o f multiple experiments with DB46, MCF7 and MDA-MB-435 with both
ALA and Photofrin®-mediated PDT.
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Table II
Flow Cytometry Analysis o f MDA-MB-435 cells______
Dose (J/cm^)
G1 (%)
G2 (%)
S (%)
Apoptosis (%)
24 hours after ALA-mediated PDT
0.14
0
31.97
21.85
46.18
2
28.61
1.57
28.20
43.20
4
31.91
18.16
49.93
10.44
46.82
20
25.99
29.92
23.26
48 hours after ALA-mediated PDT
0
40.37
22.77
36.86
1.58
2
33.19
24.87
41.93
2.20
4
25.35
24.53
50.12
13.55
50.64
20
35.61
13.75
56.39
24 hours after Photofrin®-■mediated PDT
0
40.83
19.92
39.25
0.11
2
31.64
26.31
42.05
1.11
4
42.52
32.50
24.98
5.80
20
41.30
10.71
30.93
47.98
48 hours after Photofrin®-■mediated PDT
0
40.62
35.92
23.46
2.06
2
21.72
31.82
46.46
5.06
4
32.46
21.19
46.35
6.47
20
57.67
12.80
29.52
29.86
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Table III
Flow Cytometry Analysis o f DB46 cells
Dose (J/cm )
G1 (%)
G2 (%)
S (%)
Apoptosis (%
24 hours after ALA-mediated PDT
2.94
20.31
35.05
0
44.64
18.19
34.36
2
1.68
47.44
24.08
48.62
17.10
4
27.30
19.73
42.30
14.58
20
37.97
48 hours after ALA-mediated PDT
20.32
35.34
6.47
0
44.34
26.39
38.11
3.69
2
35.50
31.38
40.35
4.00
4
28.28
43.18
17.25
27.27
20
39.57
24 hours after Photofrin®--mediated PDT
20.46
47.89
0.37
0
31.65
42.32
4.70
2
25.38
32.29
32.32
9.12
4
38.26
30.32
42.04
5.53
35.27
20
52.43
48 hours after Photofrin®--mediated PDT
17.23
39.43
0.17
0
43.34
21.54
43.44
3.21
2
35.02
19.05
49.17
4
31.79
14.27
36.79
10.42
20
34.82
52.79
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Table IV
__________ Flow Cytometry Analysis o f DC4 cells__________
Dose (J/cm"^)
G1 (%)
G2 (%)
S (%)
Apoptosis (%)
24 hours after ALA-mediated PDT
0
15.92
27.58
56.50
0.31
2
61.59
17.01
21.40
7.75
4
11.13
71.88
16.99
6.51
6.33
58.87
20
34.81
12.29
48 hours after ALA-mediated PDT
15.24
26.73
58.03
0
2.78
2
17.29
56.74
25.97
5.56
4
20.33
11.21
18.66
61.01
20
24.53
21.73
53.74
12.97
24 hours after Photofrin®--mediated PDT
24.41
0
52.08
0.37
23.51
2
52.76
18.87
28.36
9.82
4
24.08
52.74
22.17
10.76
34.11
20
50.08
15.81
37.82
48 hours after Photofrin® -mediated PDT
0
21.24
45.09
33.67
0.58
2
50.55
24.85
24.60
9.48
4
27.45
25.56
46.99
11.54
20
25.86
18.07
20.00
56.07
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Table V
_________ Flow Cytometry Analysis o f MCF7 cells_____
Dose (J/cm^)
G1 (%)
G2 (%)
S (%)
Apoptosis^
24 hours after ALA-mediated PDT
8.92
0
43.61
13.71
42.68
2
15.15
10.95
59.61
25.23
4
0.31
64.06
20.34
35.63
8.35
60.03
42.44
20
31.63
48 hours after ALA-mediated PDT
0
0
26.23
73.77
1.63
2
19.3
46.09
1.78
34.61
4
28.14
28.05
43.81
5.66
20
23.44
30.72
45.85
22.14
24 hours after Photofrin®-■mediated PDT
0
39.14
14.07
46.79
11.88
2
36.72
7.49
20.06
55.79
4
55.72
16.68
35.01
9.28
20
0.63
60.07
54.18
39.3
48 hours after Photofrin®--mediated PDT
0
8.64
48.5
42.86
10.19
2
17.05
42.82
17.54
40.13
4
21.89
39.64
31.6
38.47
24.32
20
12.31
63.37
45.75
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Fig. 22. Fluorescence analysis o f photosensitized cells. The amount o f photosensitizer
fluorescence per cell was determined using flow cytometry. Measurements were done
after four hours o f incubation. Varying concentrations o f ALA (A) and Photofrin® (B)
were investigated. Results are an average o f three experiments with each experiment
done in duplicate.
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Fig. 23. Fluorescence analysis o f photosensitized cells at varying times. Fluorescence o f
photosensitized tumor cells was investigated with varying times. ALA (A) was used at a
concentration o f 1 mM. Photofrin® (B) was investigated at a concentration o f 2.5 pg/mL.
All values were normalized to the zero point (not shown). Values are an average o f 2
separate experiments, each experiment was done in duplicate.
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Fig. 24. Attachment assay of MDA-MB-435 cells after ALA-mediated PDT. ALAmediated PDT induces detachment and necrosis o f MDA-MB-435 cells. The number o f
attached cells (A) and the number o f cells found in the media (B) was normalized to total
(attached plus floating cells) found in the control flasks at time zero. Each data point was
done in duplicate. Data is representative o f two experiments.
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Fig. 25. Attachment assay o f MDA-MB-435 cells after Photoftin®-mediated PDT.
Photofrin®-mediated PDT causes detachment and necrosis in MDA-MB-435 cells. The
number o f attached cells (A) and the number o f cells found in the media (B) was
normalized to total (attached plus floating cells) found in the control flasks at time zero.
Each data point was done in duplicate. Data is representative o f two experiments.

67

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

120-1

<n
g 100-

0 J/cm
2 J/cm^

■S 80-

I

60-

"c

40-

i

0.

10 J/cm'

20

-

0

1

3

2

4

5

Time (hr)

B
30-1
0 J/cm
2 J/cm^

P 20-

•“ 10 J/cm'

1 0 -‘

0

1

2

3

4

5

Time (hr)

Fig. 26. Attachment assay o f BT 4 C cells after ALA-mediated PDT. ALA-mediated PDT
induces detachment and necrosis on BT4C cells. The number o f attached cells (A) and
the number o f cells found in the media (B) was normalized to total (attached plus floating
cells) found in the control flasks at time zero. Each data point was done in duplicate.
Data is representative o f two experiments.
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Fig. 27. Fluorescent microscopy studies with ALA-mediated PDT. Breast cancer cells
(MDA-MB-435 and MCF7) and brain cancer cells (F98 and BT 4 C) were treated with
ALA-mediated PDT and analyzed with fluorescent microscopy 48 hours after treatment.
Hoechst stain is an indicator o f apoptosis and PI is an indicator o f necrosis. The number
o f cells were counted in the bright field image and the cells that were positive for staining
were normalized to the total number o f cells.
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Fig. 28. Fluorescent microscopy study o f MDA-MB-435 cells. 24 and 48 hours after
treatment MDA-MB-435 cells were analyzed with Hoechst and PI stain to identify
apoptotic and necrotic cells. The total number o f cells in the bright field was used to
normalize the number o f cells positive for each stain. Data is an average o f two
experiments with three pictures taken in each well.
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Fig. 29. Protein oxidation after ALA-mediated PDT. ALA-mediated PDT causes more
thiol oxidation in breast cancer cell lines than in brain cancer cell lines. The number o f
reduced thiol groups was measured using Ellman’s reagent immediately after ALAmediated PDT treatment. The values were normalized to the 0 point, which received
ALA, but no light treatment. Values are a combination o f at least 2 experiments. * = p
<0.05
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Fig. 30. Protein oxidation o f MDA-MB-435 cells with BSO and vitamin E. Photofrin®
has less thiol oxidation at equal survival levels. 2.5 and 0.5 J/cm2 are the approximate
EC50 values for ALA (A) and Photofrin® (B) mediated PDT, respectively. At 4 and 2
J/cm2 there is less than 90% survival for ALA and Photoftin®-mediated PDT,
respectively. The number o f reduced thiol groups was measured using Ellman’s reagent
immediately after PDT treatment. The values were normalized to the 0 point, which
received photosensitizer, but no light treatment. Both BSO and vitamin E samples were
pre-treated for 24 hours with the drugs before PDT. Values are a combination o f at least
2 experiments. * = p< 0.05
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Fig. 31. Protein oxidation of MDA-MB-435 cells after PDT. Thiol oxidation is not dose
dependent with ALA or Photofrin®-mediated PDT. MDA-MB-435 cells were treated
with both Photofiin® and ALA-mediated PDT. The number o f reduced thiol groups was
measured using Ellman’s reagent immediately after ALA or Photofnn®-mediated PDT
treatment. The values were normalized to the 0 point, which received the photosensitizer,
but no light treatment. Values are a combination o f at least 2 experiments. * = p <0.05
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Fig. 32. Lipid peroxidation measured using HPLC. MDA-MB-435 cells were analyzed
immediately after PDT treatment. Quantification o f MDA was normalized to total
protein content. Control values were subtracted from each data point. Data is a
combination o f three separate experiments.
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Fig. 33. Fluorescent microscopy o f MDA-MB-435 cells after PDT. MDA-MB-435 cells
were analyzed with Hoechst and PI stain 24 hours after PDT to identify apoptotic and
necrotic cells. The total number o f cells in the bright field was used to normalize the
number o f cells positive for each stain. Data is an average o f two experiments with three
pictures taken in each well.
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Fig. 34. Clonogenic survival o f MDA-MB-435 cells with BSO and vitamin E. MDAMB-435 cells were treated with ALA-mediated PDT and clonogenic survival assays were
performed. Graph shown is a combination o f two experiments. In each experiment, each
data point was done in triplicate. BSO and vitamin E were applied 24 hours prior to
irradiation at a concentration o f 50 pM. * = p <0.05
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Fig. 35. Clonogenic survival o f DB46 cells with BSO and vitamin E. DB46 cells were
treated with ALA-mediated PDT and clonogenic survival assays were performed. Graph
shown is a combination o f two experiments. In each experiment, each data point was
done in triplicate. BSO and vitamin E were applied 24 hours prior to irradiation at a
concentration o f 50 pM. * = p <0.05
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Fig. 36. Clonogenic survival o f DC4 cells with BSO and vitamin E. DC4 cells were
treated with ALA-mediated PDT and clonogenic survival assays were performed. Graph
shown is a combination o f two experiments. In each experiment, each data point was
done in triplicate. BSO and vitamin E were applied 24 hours prior to irradiation at a
concentration o f 50 pM. * = p <0.05
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Fig. 37. Clonogenic survival o f MCF7 cells with BSO and vitamin E. MCF7 cells were
treated with ALA-mediated PDT and clonogenic survival assays were performed. Graph
shown is a combination o f two experiments. In each experiment, each data point was
done in triplicate. BSO and vitamin E were applied 24 hours prior to irradiation at a
concentration o f 50 pM. * = p <0.05

79

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

120
BSO
No addition
Vitamin E

f 11 a | n _ ^
4.0

10.0

Photofrin-mediated PD T - Light Irradiation (J/cm^)

Fig. 38. Clonogenic Survival o f MDA-MB-435 with Photofrin®, BSO and vitamin E.
MDA-MB-435 cells were treated with Photofrin®-mediated PDT and clonogenic survival
assays were performed. Graph shown is a combination o f two experiments. In each
experiment, each data point was done in triplicate. BSO and vitamin E were applied 24
hours prior to irradiation at a concentration o f 50 pM. * = p <0.05
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Fig. 39. Clonogenic survival o f DC4 cells with Photofrin® and vitamin E. DC4 cells
were treated with Photofrin®-mediated PDT and clonogenic survival assays were
performed. Graph shown is a combination o f two experiments. In each experiment, eaeh
data point was done in triplicate. Vitamin E was applied 24 hours prior to irradiation at a
concentration o f 50 pM. * = p <0.05
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Fig. 40. Flow Cytometry Analysis o f cell cycle distribution. DC4 (A) and DB46 (B)
cells were treated with Photofnn®-mediated PDT and vitamin E. PI was used to stain the
DNA o f the cells. Vitamin E was applied to cells 24 hours prior to irradiation at a
concentration o f 50 pM. Cells were harvested at 24 and 48 hours after irradiation.
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Fig. 41. Fluorescence o f MDA-MB-435 cells with Photofrin® and vitamin E. MDA-MB
435 cells were treated with 0 or 2.5 pg/mL o f Photofrin®. Vitamin E was applied 24
hours prior to analyzing eells at a eoncentration o f 50 pM. Cell fluorescence was
measured using flow eytometry.
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Fig. 42. Oxidative sensitive probe with BT 4 C cells. BODIPY C n probe was loaded into
cells 15 minutes before irradiation. BT4 C cells were treated with ALA-mediated PDT
and then analyzed. The probe fluorescence was measured with the fluorescent
microscope and images were taken with a blue and green filter. The change from red to
green fluorescence signifies oxidation. A, C and E are the phase contrast images o f B, D
and F respectively. B, D and F are the fluorescent images taken and merged to give the
red and green fluorescent image. A and B are the control images receiving no light
irradiation. C and D are the 4 J/cm^ images and E and F are the 10 J/cm^ images.
Pictures are representative of three shots taken per treatment.
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Fig. 43. Oxidative sensitive probe with MCF7 cells. BODIPY C n probe was loaded into
cells 15 minutes before irradiation. MCF7 cells were treated with ALA-mediated PDT
and then analyzed. The probe fluorescence was measured with the fluorescent
microscope and images were taken with a blue and green filter. The change from red to
green fluorescence signifies oxidation. A, C and E are the phase contrast images o f B, D
and F respectively. B, D and F are the fluorescent images taken and merged to give the
red and green fluorescent image. A and B are the control images receiving no light
irradiation. C and D are the 4 J/cm^ images and E and F are the 10 J/cm^ images.
Pictures are representative o f three shots taken per treatment.
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Fig. 44. Oxidative sensitive probe with MDA-MB-435 cells treated with ALA-mediated
PDT. BODIPY C n probe was loaded into cells 15 minutes before irradiation. The probe
fluorescence was measured with the fluorescent microscope and images were taken with
a blue and green filter. The change from red to green fluorescence signifies oxidation.
A, C and E are the phase contrast images o f B, D and F respectively. B, D and F are the
fluorescent images taken and merged to give the red and green fluorescent image. A and
B are the control images receiving no light irradiation. C and D are the 4 J/cm^ images
and E and F are the 10 J/cm^ images. Pictures are representative o f three shots taken per
treatment.
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Fig. 45. Oxidative sensitive probe with MDA-MB-435 cells treated with Photofrin mediated PDT. BODIPY C n probe was loaded into cells 15 minutes before irradiation.
The probe fluorescence was measured with the fluorescent microscope and images were
taken with a blue and green filter. The change from red to green fluorescence signifies
oxidation. A, C and E are the phase contrast images o f B, D and F respectively. B, D
and F are the fluorescent images taken and merged to give the red and green fluorescent
image. A and B are the control images receiving no light irradiation. C and D are the 4
J/cm^ images and E and F are the 10 J/cm^ images. Pictures are representative o f three
shots taken per treatment.
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CHAPTER 4

DISCUSSION
In these studies, it has been shown that ALA and Photofrin®-mediated PDT are
effective in inducing cell death (both apoptosis and necrosis) in rat glioma cell lines and
human breast eancer cell lines. Oxidation o f proteins and lipids was deteeted with both
photosensitizers. Photofrin® and ALA-mediated PDT have eaeh been shown to cause
cell cytotoxicity by two different mechanisms. A summary o f these differences is
presented in Table VI (page 100).
The effectiveness o f PDT is dependent on both light irradiance and
photosensitizer application (Fig 9, page 46) whieh is in good agreement with published
results. In these studies, breast eaneer eell lines are more sensitive to Photofrin® than to
ALA-mediated PDT (Table I, page 58). For the four breast cancer eell lines studied the
ECso values were signifieantly lower for the Photofrin®-mediated PDT than the ALAmediated PDT. Not only is the EC 5 0 lower in the Photofrin® treated eells, but they reaeh
an EC90 at lower doses o f light than the ALA treated cells. The observation that
Photofrin® is more lethal than ALA is supported by the flow cytometry analysis o f the
breast cancer cells (Table II-IV, pages 60-63). The trend that the amount o f apoptotie
vesicles was higher in the Photofrin® treated cells than the ALA treated cells is observed.
The comparison that Photofrin® is more effective than ALA-mediated PDT has been
reported earlier by other groups (33, 34). This comparison o f the two photosensitizers is
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not clinically relevant because in vivo ALA and Photofrin target different types o f
tissues. Photofrin® targets vaseulature within the tumor where ALA targets the tumor
cells specifically (35, 36). Since the two photosensitizers have different effeets within
the patient, it may not be elinieally relevant that Photofiin® is more effective against
breast cancer cell lines in vitro.
In these studies the two rat glioma cell lines eompared to the four breast cancer
eell lines were shown to be more resistant to ALA-mediated PDT. This can be seen by
examining the EC 5 0 values o f the BT 4 C and the F98, (Table 1, page 58) which occur at
higher doses than the breast cancer cell lines investigated. Also, when examining the
clonogenie survival results, the glioma cell lines did not reach an EC 9 0 value o f 20 J/cm^.
This is different than the breast cancer cell lines which did reach EC 9 0 values before 20
J/em^. This difference between the two types o f eell lines could be either a tissue or
species specific difference or both. There are intrinsic differences when comparing two
different species models. It is also true that gliomas are resistant to treatment with
conventional therapies (37).
The fluorescence properties o f photosensitizers have been utilized in imaging o f
tumor locations and can aid in diagnostic practices (38). The relative amount of
fluorescenee o f ALA induced PpIX and Photofrin® can also allow us to estimate the
concentration o f photosensitizer within the cell. When comparing PpIX and Photofrin®
fluorescence levels, it is observed that Photofrin® has a 10 times higher amount o f
fluorescence per cell. This is most likely due to the intrinsic fluorescence o f Photofrin®.
When looking at the overall trends o f ALA and Photofrin® fluorescence by varying
coneentrations, it is seen that in most o f the cell lines there is a maximum fluoreseence
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that is obtained at 1 mM ALA (Fig. 22, page 64). With Photofrin a maximum
fluorescence is not reached by a concentration o f 10 pg/mL. This could indicate that
with increasing the concentration o f ALA above 1 mM will not change the concentration
o f PpIX within the cell. The same trends that were seen with varying concentrations are
also seen when time is varied with both ALA and Photofrin® (Fig. 23, page 65). After
three hours of incubation with ALA most o f the cell lines reach a maximal concentration
o f PpIX and incubation for longer times would not increase that level. With Photofrin®,
there is no maximal concentration reached by five hours and incubation for longer times
might produce a higher concentration o f Photofrin®. Unfortunately, the fluorescence
levels are not comparable between the concentration and time variance experiments. The
MCF7 cells incubated with ALA have fluorescence o f 100 a.u. in Fig. 22 and 600 a.u. in
Fig. 23 under the same incubation conditions. These variations in fluorescence are seen
with all cell lines and both photosensitizers and deserve further investigation.
When analyzing the ALA induced PpIX fluorescence, the MCF7 cells have the
highest fluorescence levels which correlate to the MCF7 cells being the most sensitive to
ALA-mediated PDT as seen by the low EC 5 0 value. It has been reported that there is a
correlation with increased PpIX concentrations within the cell and higher effectiveness o f
tumor cell line killing which is consistent with the data reported here (39). It is also
important to note that MCF7 cells are the only caspase 3 deficient cell line that was
investigated. This lack o f caspase 3, increased PpIX production or another factor not yet
determined may be leading to higher levels o f cell death. The other four cell lines
investigated had relatively similar levels o f PpIX fluorescence. PpIX production is not
the only factor that leads to cell sensitivity since the BT 4 C cells, which were the least
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sensitive to ALA-mediated PDT, showed a similar fluorescence level with the MDAMB-435, DC4 and DB46 cells.
Photofrin® fluorescence does not correlate with elonogenic survival results. The
MCF7 cells were again the most sensitive to the Photoffin®-mediated PDT in the
elonogenic survival, but had the second lowest Photofrin® fluorescence. The DC4, DB46
and MDA-MB-435 cells all had similar EC 5 0 values, but the DC4 and DB46 cells showed
higher amounts o f fluorescence as compared to the MDA-MB-435. From this data it can
be concluded that PpIX production may have an effect on sensitivity o f the four cells to
ALA-mediated PDT, but there are other factors that affect sensitivity. With Photofiin®mediated PDT, Photofrin® concentration within the cell does not have a direct correlation
with sensitivity. Other studies have reported that the amount o f photosensitizer within
the cell does not always correlative to cell survival (40). It may be hypothesized that
there is a threshold amount o f Photofrin® that must be incorporated into the cell to
achieve sensitivity, but concentrations above that amount do not effect sensitivity. In the
studies reported here it may be assumed that the threshold level o f Photofrin® was
obtained by a concentration of 2.5 pg/mL o f Photofrin® since fluorescence levels of
Photofl-in® are not correlative with survival.
It has been reported that both apoptosis and necrosis occurs after PDT induced
cytotoxicity (41, 42). It has also been reported that two different apoptotic pathways are
induced during ALA-mediated PDT (42, 43). In the studies reported here, earlier reports
are confirmed and show a timeline o f two types o f cell death occurring which appears to
be dose and photosensitizer dependent. The exact molecular mechanism that causes cell
death has not been reported for either ALA or Photoftin®-mediated PDT. There are
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many speculations on the molecular mechanism, but a specific pathway has not been
confirmed. Because o f this, ALA and Photofrin® induced mechanisms o f cell death have
not been compared to each other extensively in the literature. Here it is reported that
ALA and Photofrin®-mediated PDT have two different timelines o f cell death that may
indicate two different molecular mechanisms.
With ALA-mediated PDT it was observed that there was a fast type o f cell death
which is characteristic o f necrosis and a slow type o f cell death characteristic of
apoptosis. This was confirmed with fluorescent microscopy, flow cytometry and
attachment assays. With Photofiin®-mediated PDT, cell death is mostly necrotic and
happens more quickly than the ALA-mediated PDT induced cell death. When looking at
fluorescent microscopy results, the ALA-mediated PDT cells have early necrotic events
seen at the 24 hour time point and that decrease by the 48 hour time point (Fig. 28, page
70). There is the presence o f apoptotic cells both at 24 and 48 hours. With Photofiin®mediated PDT fluorescent microscopy results indicate that there are high amounts o f
necrosis at all light doses at the 24 hour time point with a decrease in the amount o f
necrosis at the 48 hour time point. A small amount o f apoptosis can only be observed at
low doses at the 48 hour time point.
The fact that there are two types o f cell death is also supported by the data from
the attachment assays and flow cytometry. In the attachment assays, there was a
detachment and loss o f cells within four hours with both ALA and Photofrin®-mediated
PDT (Fig. 24-26, pages 66-68). Loss o f cells is characteristic o f necrotic cell death.
Flow cytometry results also confirm that Photofrin® and ALA-mediated PDT are using
two different mechanisms of cell death. With ALA-mediated PDT there was an increase
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in the number o f apoptotic cells between the 24 and 48 hour time points with all cell
lines. With the Photoffin®-mediated PDT there was a decrease or no change in the
number o f apoptotie cells between the 24 and 48 hour time points. Flow eytometry also
showed a general decrease in the S phase o f the cell cycle as the dose o f Photoffin®mediated PDT was increased. This may indicate a block in the cell cycle that is not
evident with ALA mediated-PDT. This trend was not observed in the ALA-mediated
PDT cells.
Another observation that can be made from these studies was that the rat glioma
cell lines have a different response to ALA-mediated PDT than the breast cancer cell
lines. It has been reported that brain tissue will undergo both apoptosis and necrosis after
PDT treatment (44). It is also logical to expect differences in eell death with two tissues
that are as different as brain and breast tissue. Brain tissue is unique in the lipids that are
found within the eell. Lipids play an important role in ALA-mediated PDT induced
apoptosis, which could explain these differences (45). In our studies we see much higher
levels o f apoptosis in brain cells treated with ALA-mediated PDT than the breast cancer
cells treated. This is actually beneficial in the clinical setting as apoptosis does not
induce inflammation and does not cause eell death to adjoining cells as necrosis does
(33).
Protein oxidation has been reported to occur after PDT treatment in different
types o f eell systems, but not always in a dose dependent response (15, 45, 46). The data
presented here supports these earlier findings. It was observed that both ALA and
Photofrin®-mediated PDT caused protein oxidation through the loss o f reduced thiol
groups. The protein oxidation was not correlative to survival levels within the cell lines
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or between the two photosensitizers. The data that is correlative to cell survival is that
the two brain eell lines, BT 4 C and F98, had the least amount o f protein oxidation and had
the highest EC50 values o f eells treated with ALA-mediated PDT. Photofrin® has been
shown to be more effective than ALA-mediated PDT in killing the MDA-MB-435 cells,
yet it had lower amounts o f protein oxidation at both equal survival and equal doses.
This again points to two different types o f cell death between the Photofrin® and ALAmediated PDT treated eells. Because the protein oxidation is not dose dependent with
survival, apoptosis levels or necrosis levels, it suggests that a bulk oxidation o f protein is
not the key to the switch between apoptosis and necrosis within the cell.
Lipid peroxidation has also been reported in conjunction with PDT induced
cytotoxicity (47). However, it has been suggested though that lipid peroxidation is not
the general mechanism that produces eell death in PDT treated eells (40, 48). The data
reported here supports these earlier findings. There is an increase in lipid peroxidation
after PDT treatment with both ALA and Photofrin®-mediated PDT. Increased lipid
peroxidation does not reach a significantly higher level than control until higher doses o f
light irradiation. This is not correlative to survival data, since there is no increase in lipid
peroxidation above basal level until after the EC50 dose in both ALA and Photoffin®mediated PDT cells. Also the ALA treated cells show a higher amount o f lipid
peroxidation as compared to the Photofrin® treated eells. This is not correlative with the
observed effects in the elonogenic survivals. There is not a clear correlation o f lipid
peroxidation and apoptosis. Lipid peroxidation has been reported to cause apoptosis,
which our studies do not support (41). This could be due to a targeted analysis by Kriska
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et al. o f mitochondrial lipids as compared to the studies done in this manuscript where the
whole cell was analyzed (41).
The application of antioxidants and PDT have been investigated in a number of
studies since they can play an important role in the oxidative stress a cell undergoes.
Vitamin E and vitamin C have been shown to protect cells against PDT (49, 13). It has
also been shown by a single research group that Foscan-mediated PDT can be enhanced
by vitamin E application (48, 50). The data presented here supports both o f these
findings. Vitamin E was shown to protect cells against ALA and Photofrin®-mediated
PDT in the elonogenie survival assays. But in other assays vitamin E was shown to
sensitize cells to Photofrin®-mediated PDT. This was evident when looking at protein
oxidation, fluorescent microscopy and flow cytometry. It was first thought that this was a
function o f increased Photofrin® concentration within the cell. This was not the case, as
fluorescence studies were done.

It was undetermined as to the reason for both

proteetion and sensitization that vitamin E had during PDT treatments.
It has been reported that BSD can enhance Photofrin®-mediated PDT by lowering
GSH levels within the cell (51). The effects BSD has in conjunction with ALA-mediated
PDT have not been reported. In our studies we have shown that BSD selectively
sensitizes cells to ALA-mediated PDT. It would be expected that by lowering the levels
o f GSH within the cell that there would be increased oxidative stress. In Photoffin®mediated PDT cells there was increased protein oxidation with application o f BSD, but
not in cells treated with ALA-mediated PDT. BSD sensitized the breast cancer cells,
MCF7, DC4 and DB46, to ALA-mediated PDT, but did not in the MDA-MB-435 cells.
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These findings confirm that the mechanism o f eell death is not as simple as changes in
bulk levels o f oxidation, changing the sensitivity o f tumor cells to PDT.
Since the total amount o f lipid or protein oxidation within the cell does not seem
to be correlative with eell survival, it was hypothesized that a target or set o f targets may
be the key to PDT induced cell death. It has been reported that ALA induced PpIX and
Photofrin® localize in different areas o f the cell, which may lead to different targets o f
oxidation. PpIX localization within the cell has been said to be mitochondrial bound (41,
52). Photofrin® is highly lipophillic, associates with high density lipoproteins, and can be
found in the cellular, endoplasmic reticulum and nuclear membranes (9, 53). To confirm
the different localization patterns o f the photosensitizers, fluorescent microscopy was
used with a fluorescent probe to determine lipid oxidation patterns. Unfortimately, with
the data obtained, it was not possible to conelusively determine any localization patterns
within the cellular organelles with Photofi-in® or ALA-mediated PDT. Fluoreseenee
studies with the photosensitizers alone may help to determine the loeation o f the
photosensitizer within the eell. Also the use o f a secondary dye specific to organelles
within the cell may be useful in determining the localization patterns o f the
photosensitizers.
ALA-mediated PDT induced cytotoxicity has been investigated by many different
research groups. Shahzidi et al. showed that ALA-mediated PDT caused the loss o f
membrane potential o f the mitochondria, the release o f cytochrome c and the activation
o f caspase 3 and caspase 9 (54). At this time, there have been no conclusive reports
about the role o f caspase 8 in cell death induced by ALA-mediated PDT. There have
been investigations that have shown that along with mitochondrial changes within the

96

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

cell, the disruption o f the aetin filaments leads to necrosis in ALA-mediated PDT treated
cells (55). Finlan et al. reported that ALA-mediated PDT induced DNA damage, but did
not induce the activation o f p53 (56). It has also been reported that ALA-mediated PDT
induces the production o f Hsp70 in response to the stress o f PDT (57). These studies
show that ALA-mediated PDT induces eell death that is characteristic o f apoptosis
through mitochondrial signaling.
Photofrin®-mediated PDT induces eell death that is similar to that o f ALAmediated PDT. Wu et al. showed the activation o f caspase 3 within Photofrin® treated
cells, but not an activation in caspase 8 (53). Unlike the ALA-mediated PDT cells,
Photofrin®-treated PDT cells showed an induction o f the p53 pathway (58, 59). Takahira
et al. demonstrated that DNA ladder formation occurred after Photofrin®-mediated PDT
along with the activation o f caspase 3 and caspase 9 and concluded that mitochondrial
damage was important to apoptosis activation (60). The induction o f Hsp70 after
Photofrin®-mediated PDT has also been reported (61, 62). Overall, Photofirin®-mediated
PDT treated cells shows the general hallmarks o f apoptosis which is similar to the ALAmediated PDT treated cells.
Even though in our studies we have seen distinct differences in the type o f eell
death in ALA and Photofrin®-mediated PDT treated cells, this is not necessarily what has
been reported earlier. Unfortunately there have not been many studies conducted that
compare Photofrin® to ALA with the same cell line and same treatment conditions.
When comparing the mechanism o f ALA and Photofrin® it is important to have similar
experimental conditions, since incubation times, laser conditions and cell lines all can
give unique results. One o f the strengths o f the studies reported here is that similar
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treatment conditions have been used. This allows for the direct comparison o f ALA and
Photofrin®. Another problem with earlier reports is that the same hallmarks o f cell death
have not been reported on for both photosensitizers. Caspase 8 for instance has been
reported to not be activated in Photofrin®-mediated PDT, but there are no reports on its
effect with ALA-mediated PDT. In the studies reported here by using the same assays
for both ALA and Photofrin® treated cells a direct comparison can be made between the
two photosensitizers.

Summary - There is now preliminary data to show that Photofrin® and ALA-mediated
PDT are inducing cell death by two different types o f molecular mechanisms. While
both ALA and Photofrin®-mediated PDT induce apoptosis, the data presented in this
study indicate they do so by two unique mechanisms. There is also evidence that it is not
just the amount o f bulk lipid or protein oxidation that determines whether apoptosis,
necrosis or cell survival will occur after PDT treatment. A specific set o f targets may be
the key to understanding the mechanism behind cell cytotoxicity after PDT.
To further study the molecular mechanism it may be important to look at the last
set o f molecules that can be oxidized, DNA. Photosensitizers have been shown to bind to
DNA within the nucleus (13, 63). The key to the difference in molecular mechanism
between apoptosis and necrosis with ALA and Photofrin®-mediated PDT may be due to
DNA binding properties of the photosensitizer or location o f the oxidation o f the DNA.
This could also explain the decrease in the S phase peak when Photofrin®-mediated PDT
is used. Looking at DNA binding and oxidation with PDT may be the key to the
molecular mechanism.
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Also, further studies should look at the role o f the membrane components with
PDT. Looking at the specific lipids within the cells that get targeted for oxidation during
PDT might also prove useful. Glial eells have different lipid content as compared to
other tissues, and this may be the reason for decreased sensitivity in this cell type.
Vitamin E is also a lipophillie molecule that associates with cellular membranes. The
results presented here do not conclusively explain vitamin E ’s role in PDT. Photofrin®
associates with lipoproteins within the membrane (9). These important factors may also
point to an important membrane component o f PDT-induced cytotoxicity. By
modulating the lipid content within the eell, it may become clear how to increase the
effectiveness o f PDT (64).
Finally, to improve the clinical application o f PDT, it is important to understand
how combination therapies affect PDT effectiveness. Breast cancer patients today are not
given a single therapy. Multiple therapies are used and most breast cancer patients will
receive chemotherapy in addition to other treatments. Understanding the effects o f PDT
with other chemotherapeutic agents is important. It may be found that synergistic
combinations exist along with negative combinations. Not only should these be done at
the cellular level, but in vivo work should also be carried out. Photofrin® and ALA work
differently in vivo than what is seen at the cellular level. Having this knowledge will help
physicians incorporate PDT into the normal regimen o f cancer therapies.
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Experiment
Survival
Auto Fluoreseenee
Cell Counts
Fluorescent Micro.
Protein Oxidation
Lipid Peroxidation
Flow Cytometry
BSO Survival
Vitamin E Survival

Table VI
Summary o f Results
ALA-mediated PDT
Photofirin®-mediated PDT
Less Lethal
More Lethal
Less
More
Less Detachment
More Detachment
More Apoptosis
More Necrosis
More
Less
More
Less
Less Apoptosis
More Apoptosis
Sensitivity
Sensitivity
Protection
Protection
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